Cargando…

Psychosocial Impact and Disease Management in Patients with Congenital Factor VII Deficiency

PURPOSE: Congenital factor VII (FVII) deficiency is a rare bleeding disorder of variable phenotype with predominantly mucocutaneous bleeding. The aim of this study was to identify the burden of FVII deficiency on patients and caregivers through a better understanding of the management and psychosoci...

Descripción completa

Detalles Bibliográficos
Autores principales: Peltier, Skye, Kellum, Angela, Brewer, Janet, Duncan, Alexander, Cooper, David L, Saad, Hossam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494225/
https://www.ncbi.nlm.nih.gov/pubmed/32982528
http://dx.doi.org/10.2147/JBM.S259909
_version_ 1783582704465346560
author Peltier, Skye
Kellum, Angela
Brewer, Janet
Duncan, Alexander
Cooper, David L
Saad, Hossam
author_facet Peltier, Skye
Kellum, Angela
Brewer, Janet
Duncan, Alexander
Cooper, David L
Saad, Hossam
author_sort Peltier, Skye
collection PubMed
description PURPOSE: Congenital factor VII (FVII) deficiency is a rare bleeding disorder of variable phenotype with predominantly mucocutaneous bleeding. The aim of this study was to identify the burden of FVII deficiency on patients and caregivers through a better understanding of the management and psychosocial impact of this disease. MATERIALS AND METHODS: A rare disease specialty recruiter from Comprehensive Health Education Services recruited participants for this online survey, which was conducted from January 31 to March 12, 2019. A moderator-assisted questionnaire was used to collect data on demographics, diagnosis, treatment, and psychosocial impact. RESULTS: Of the 45 respondents (25 patients and 20 caregivers), the majority were female (56%). Respondents reported a wide variety of initial bleeding symptoms, including bruising (58%), epistaxis (56%), and menorrhagia (36% of females). Because symptoms varied between individuals and were not always severe, diagnosis was often delayed. Mean time to obtain a diagnosis was 6.5 years and mean age at first diagnosis was 12.9 years. One-quarter (24%) of the respondents reported more than 100 bleeds of any severity over the previous year. When treating bleeds, 44% of patients reported using antifibrinolytics, and 42% reported using recombinant activated factor VII. Almost 31% of respondents reported missing schooldays as children, and 16% reported losing or resigning from a job in adulthood as a direct result of their disease. Notably, 29% of caregivers and 10% of their partners had also experienced issues with employment. Forty percent of respondents reported not participating in contact sports during childhood, and 22% continued to avoid contact sports in adulthood. CONCLUSION: Overall, FVII deficiency has a substantial psychosocial impact, but most patients are satisfied with their disease management and are optimistic about their future. Patients desire additional educational, social, and financial support.
format Online
Article
Text
id pubmed-7494225
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74942252020-09-24 Psychosocial Impact and Disease Management in Patients with Congenital Factor VII Deficiency Peltier, Skye Kellum, Angela Brewer, Janet Duncan, Alexander Cooper, David L Saad, Hossam J Blood Med Original Research PURPOSE: Congenital factor VII (FVII) deficiency is a rare bleeding disorder of variable phenotype with predominantly mucocutaneous bleeding. The aim of this study was to identify the burden of FVII deficiency on patients and caregivers through a better understanding of the management and psychosocial impact of this disease. MATERIALS AND METHODS: A rare disease specialty recruiter from Comprehensive Health Education Services recruited participants for this online survey, which was conducted from January 31 to March 12, 2019. A moderator-assisted questionnaire was used to collect data on demographics, diagnosis, treatment, and psychosocial impact. RESULTS: Of the 45 respondents (25 patients and 20 caregivers), the majority were female (56%). Respondents reported a wide variety of initial bleeding symptoms, including bruising (58%), epistaxis (56%), and menorrhagia (36% of females). Because symptoms varied between individuals and were not always severe, diagnosis was often delayed. Mean time to obtain a diagnosis was 6.5 years and mean age at first diagnosis was 12.9 years. One-quarter (24%) of the respondents reported more than 100 bleeds of any severity over the previous year. When treating bleeds, 44% of patients reported using antifibrinolytics, and 42% reported using recombinant activated factor VII. Almost 31% of respondents reported missing schooldays as children, and 16% reported losing or resigning from a job in adulthood as a direct result of their disease. Notably, 29% of caregivers and 10% of their partners had also experienced issues with employment. Forty percent of respondents reported not participating in contact sports during childhood, and 22% continued to avoid contact sports in adulthood. CONCLUSION: Overall, FVII deficiency has a substantial psychosocial impact, but most patients are satisfied with their disease management and are optimistic about their future. Patients desire additional educational, social, and financial support. Dove 2020-09-11 /pmc/articles/PMC7494225/ /pubmed/32982528 http://dx.doi.org/10.2147/JBM.S259909 Text en © 2020 Peltier et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Peltier, Skye
Kellum, Angela
Brewer, Janet
Duncan, Alexander
Cooper, David L
Saad, Hossam
Psychosocial Impact and Disease Management in Patients with Congenital Factor VII Deficiency
title Psychosocial Impact and Disease Management in Patients with Congenital Factor VII Deficiency
title_full Psychosocial Impact and Disease Management in Patients with Congenital Factor VII Deficiency
title_fullStr Psychosocial Impact and Disease Management in Patients with Congenital Factor VII Deficiency
title_full_unstemmed Psychosocial Impact and Disease Management in Patients with Congenital Factor VII Deficiency
title_short Psychosocial Impact and Disease Management in Patients with Congenital Factor VII Deficiency
title_sort psychosocial impact and disease management in patients with congenital factor vii deficiency
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494225/
https://www.ncbi.nlm.nih.gov/pubmed/32982528
http://dx.doi.org/10.2147/JBM.S259909
work_keys_str_mv AT peltierskye psychosocialimpactanddiseasemanagementinpatientswithcongenitalfactorviideficiency
AT kellumangela psychosocialimpactanddiseasemanagementinpatientswithcongenitalfactorviideficiency
AT brewerjanet psychosocialimpactanddiseasemanagementinpatientswithcongenitalfactorviideficiency
AT duncanalexander psychosocialimpactanddiseasemanagementinpatientswithcongenitalfactorviideficiency
AT cooperdavidl psychosocialimpactanddiseasemanagementinpatientswithcongenitalfactorviideficiency
AT saadhossam psychosocialimpactanddiseasemanagementinpatientswithcongenitalfactorviideficiency